Powered by 
Google Übersetzer
Google Übersetzer
KRTL Holding Group, Inc., now known as QUEENCH, Inc., (OTC: QENC) is pleased to announce its wholly owned subsidiary, KRTL Biotech Inc., ("KRTL"), today has created a partnership with Pervasip Corp. (OTC: PVSP) a developer of companies and technologies in high value emerging markets, to develop and launch a wellness joint venture.
KRTL Biotech and Pervasip collectively referred to as the “Parties”, building on years of development, combined with a network of world-renowned stakeholders in the wellness space, announce the development of the Artizen Wellness joint venture to bring high quality wellness and nutritional foods products to market. Using proprietary formulations targeting mood, mental health and various ailments, Artizen Wellness will use unique low-THC cannabinoids (CBD/CBG/other), terpenes and well-known plant extracts to develop a range of products for worldwide distribution.
According to consulting firm McKinsey’s April 2021 Global Wellness Market survey, reconfirmed in 2022, consumers globally are spending approximately $1 trillion on wellness products. Natural, clean products are the #1 rising trend with 41 percent over 21 percent choosing natural supplements over more effective ones, a welcome trend that supports Artizen Wellness’ relentless focus on clean, natural compounds backed by peer reviewed research and proven efficacy.
“I am extremely excited about the potential of this venture. We have been very fortunate to bring together a group of passionate experts in various fields, spanning traditional medical fields, alternative medicine, high quality extraction, research, and development. Combining this expertise with our Korean research network Artizen Wellness will be relentless in its focus on developing products that deliver on their promise and at a verifiable level of quality” says German Burtscher, Pervasip’s CEO & President.
The Artizen Wellness team includes leading experts like Dr. Brent LeGrange, a biochemist and biomechanics specialist who has pioneered cannabinoid based nutritional and topical products to improve mental and physical energy.
“The future of cannabis depends upon an established, well-known organization with a strong team of like-minded professionals striving to bring advanced resources and research to the industry. With these cornerstones, Artizen will bring a science-backed quality product line to the public.” Dr. Brent LaGrange.
KRTL’s CEO, Daniel Ball, brings years of relevant experience in cannabis and hemp, managing Oregon hemp farms, extraction and launching a testing lab and obtaining ISO 17025 accreditation through A2LA, the gold standard in environmental testing labs across the nation. He built his professional career on years of experience in the US Army where he, as a Signals Intelligence Analyst, quickly rose through the ranks and eventually, as a non-commissioned officer for a counter terrorism unit, managed deployment of over $250 million of ground and airborne assets in Afghanistan and other geographic theaters.
"It's very rare to have such tremendous alignment and synergy between experts with the depth of knowledge and passion this team exhibits. Everyone is committed to the highest product standards, with success metrics that prioritize the positive impact and benefit to the end user - often those dealing with chronic or recurring physical or mental pain, pain that isn't easily or effectively managed through conventional medicine but has a chance for better efficacy through complementary alternative medicine. KRTL's mission aligns perfectly with this values-based posture and we're excited to be working alongside Pervasip for this very important and very timely endeavor. There's an opportunity to elevate the trajectory of the cannabinoid and terpenoid wellness market with the introduction of highly calibrated dosing and formulation methodology alongside peer-reviewed studies and due diligence, and this team is well equipped to make that happen." Daniel Ball KRTL Biotech CEO.
Various additional personnel and companywide announcements will be made over the next few weeks and months – all with one single common thread, a relentless passion for development of the highest quality products, wellness and nutritional foods products that are science backed and have undergone rigorous development.
About KRTL Holding Group, Inc.
We translate strategy into action by combining our time-tested expertise in strategic planning, portfolio management, project execution, marketing, disruptive innovation, and organizational engagement to provide a progressive, revolutionary approach to transforming the organization. The Company manages its subsidiaries, KRTL Biotech, Inc. and KRTL International Corp., with precision and excellence and continues to create and strengthen the KRTL reputation. This allows KRTL Holding Group, Inc. to capitalize on any range of investment opportunities. Our organization values collaboration and emphasizes a transparent work environment. Pervasip additionally owns 5% of KRTL Biotech, Inc., a developer of biotechnologies with a focus on pharmaceutical applications of cannabinol and psilocybin. Additional information on KRTL is available online at www.krtlbiotech.com and www.krtlholding.com and www.krtl-icc.com . Additional information on Pervasip can be found at www.pervasip.net.
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
